Trial · NCT01071200
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Total Dose of Follicular Stimulating Hormone (FSH) for Retrieved Oocytes | Baseline (Stimulation day 8 [S8]) until hCG day | Modified intention-to-treat (mITT) population included all randomized participants who entered in the experimental phase at S8. Here N represents number of participants analyzed for this measure. | IU | MEAN |
| SECONDARY | Mean Total Follicle Stimulating Hormone (FSH) and Recombinant Human Luteinizing Hormone (r-hLH) Dose | Baseline (S8) until hCG day | mITT population included all randomized participants who entered in the experimental phase at S8. | IU | MEAN |
| SECONDARY | Mean Number of Ovarian Stimulation Days | Baseline (S8) until hCG day | mITT population included all randomized participants who entered in the experimental phase at S8. | Days | MEAN |
| SECONDARY | Change From Baseline in Oestradiol (E2) Levels at Human Choriogonadotropin (hCG) Day | Baseline (S8) and hCG day | mITT population included all randomized participants who entered in the experimental phase at S8. Here N represents number of participants analyzed and n represents the number of participants with plasma E2 levels at specified time points for respective treatment groups. | picogram/milliter (pg/mL) | MEAN |
| SECONDARY | Mean Total Number of Retrieved Oocytes | 34-36 hours post-hCG (OPU) | mITT population included all randomized participants who entered in the experimental phase at S8. | oocytes | MEAN |
| SECONDARY | Mean Number of Mature Oocytes (Metaphase II) | 34-36 hours post-hCG (OPU) | mITT population included all randomized participants who entered in the experimental phase at S8. Here N represents those participants undergoing ICSI whose oocytes were assessed for maturity (Metaphase II) using a microscope. | Metaphase II Oocytes | MEAN |
| SECONDARY | Fertilization Rate | 12-18 day post-hCG and/or Week 7 | mITT population included all randomized participants who entered in the experimental phase at S8. | ratio | MEAN |
| SECONDARY | Number of Obtained Embryos | Day 3 post-hCG (Embryo transfer [ET]) | mITT population included all randomized participants who entered in the experimental phase at S8. | embryos | NUMBER |
| SECONDARY | Number of Transferred Embryos | Day 3 post-hCG (ET) | mITT population included all randomized participants who entered in the experimental phase at S8. | embryos | NUMBER |
| SECONDARY | Percentage of Participants With Pregnancy | 12-18 day post-hCG and/or Week 7 | mITT population included all randomized participants who entered in the experimental phase at S8. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Clinical Pregnancy | 12-18 day post-hCG and/or Week 7 | mITT population included all randomized participants who entered in the experimental phase at S8. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Implantation | 12-18 day post-hCG and/or Week 7 | mITT population included all randomized participants who entered in the experimental phase at S8. | percentage of participants | NUMBER |
| SECONDARY | Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS) | Baseline (S8) until 12-18 day post-hCG and/or Week 7 | Safety population included all the randomized participants who received at least one dose of the study drug. | participants | NUMBER |
| SECONDARY | Number of Cycles Cancelled Due to Risk of OHSS | Baseline (S8) until 12-18 day post-hCG and/or Week 7 | Safety population included all the randomized participants who received at least one dose of the study drug. | cycles | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01071200/outcomes